Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 141-148

  Markert, Christoph ^a   Schweizer, Yvonne ^a   Hellwig, Regina ^a   Wirsching, Theresia ^a   Riedel, Klaus Dieter ^a   Burhenne, Juergen ^a   Weiss, Johanna ^a   Mikus, Gerd ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

bosentan; clarithromycin; CYP2C9; pharmacokinetics; polymorphism; SLCO1B1

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BOSENTAN; CLARITHROMYCIN; CREATINE KINASE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MIDAZOLAM; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; ANXIOLYTIC AGENT; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CYP2C9 GENE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; ECZEMA; ENZYME ACTIVITY; EPIGASTRIC PAIN; FATIGUE; FEMALE; FLATULENCE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOSS OF APPETITE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NIGHT SWEAT; NORMAL HUMAN; NOSE OBSTRUCTION; PRIORITY JOURNAL; RHINOPHARYNGITIS; SLCO1B1 GENE; STEADY STATE; TACHYCARDIA; TASTE DISORDER; TINNITUS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; DRUG INTERACTION; GENETICS;

ADULT; ANTI-ANXIETY AGENTS; CLARITHROMYCIN; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDAZOLAM; ORGANIC ANION TRANSPORTERS; SULFONAMIDES;

EID: 84891118336     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12177     Document Type: Article

References (30)

1. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G,. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
2. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A,. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
3. Spangler ML, Saxena S,. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin Ther 2010; 32: 53-56.
4. Treiber A, Schneiter R, Häusler S, Stieger B,. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35: 1400-1407.
5. Dingemanse J, van Giersbergen PLM,. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089-1115.
6. Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R,. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 2010; 88: 682-691.
7. Binet I, Wallnöfer A, Weber C, Jones R, Thiel G,. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 2000; 57: 224-231.
8. van Giersbergen PL, Halabi A, Dingemanse J,. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53: 589-595.
9. Dingemanse J, van Giersbergen PLM, Patat A, Nilsson PN,. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antiviral Ther 2010; 15: 157-163.
10. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dörje F, Fromm MF, König J,. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007; 35: 779-786.
11. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D,. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997; 25: 623-630.
12. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD,. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133-143.
13. Hughes J, Crowe A,. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 2010; 113: 315-324.
14. Rengelshausen J, Göggelmann C, Burhenne J, Riedel K-D, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE,. Contribution of increased oral bioavailability and reduced non-glomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003; 56: 32-38.
15. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB,. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010; 20: 277-281.
16. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G,. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 2011; 90: 666-673.
17. van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA,. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 2002; 450: 115-121.
18. Burian M, Grösch S, Tegeder I, Geisslinger G,. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002; 54: 518-521.
19. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, König S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J,. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol 2011; 67: 1139-1145.
20. FDA, US Department of Health and Human Services. Guidance for industry, bioanalytical method validation. 2001. Available at http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (last accessed 20 June 2013).
21. Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G,. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol 2013; 69: 507-513.
22. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P,. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 2012; 55: 4740-4763.
23. Jacobson TA,. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-1146.
24. Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC,. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 2001; 29: 1023-1028.
25. Burgess G, Hoogkamer H, Collings L, Dingemanse J,. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 43-50.
26. Dingemanse J, Schaarschmidt D, van Giersbergen PL,. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet 2003; 42: 293-301.
27. Weiss J, Herzog M, Haefeli WE,. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol 2011; 660: 298-304.
28. Weber C, Banken L, Birnboek H, Schulz R,. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39: 847-854.
29. Weber C, Banken L, Birnboeck H, Nave S, Schulz R,. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999; 47: 701-706.
30. Taguchi M, Ichida F, Hirono K, Miyawaki T, Yoshimura N, Nakamura T, Akita C, Nakayama T, Saji T, Kato Y, Horiuchi I, Hashimoto Y,. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet 2011; 26: 280-287.